Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
4.420
+0.040 (0.91%)
At close: Mar 20, 2026, 4:00 PM EDT
4.550
+0.130 (2.94%)
After-hours: Mar 20, 2026, 7:59 PM EDT
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
68.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 196.00K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pelthos Therapeutics | 16.80M |
| BeyondSpring | 1.88M |
| Coeptis Therapeutics Holdings | 1.36M |
| iBio, Inc. | 300.00K |
| InflaRx | 34.44K |
GRCE News
- 2 days ago - Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - GlobeNewsWire
- 24 days ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 5 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 6 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire